Comparison Between Accelerated Partial Breast Irradiation and Whole Breast Irradiation: APBI IMRT Florence Retrospective Analysis of Subjective, Objective and Patient-reported Cosmetic Outcomes

2020 ◽  
Vol 108 (3) ◽  
pp. S153
Author(s):  
I. Meattini ◽  
L.P. Ciccone ◽  
S. Lucidi ◽  
I. Desideri ◽  
L. Visani ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Accelerated Partial Breast Irradiation ◽  
Partial Breast Irradiation ◽  
Whole Breast Irradiation ◽  
Breast Irradiation ◽  
Patient Reported ◽  
Cosmetic Outcomes

scholarly journals Accelerated partial breast irradiation by brachytherapy: present evidence and future developments

2020 ◽  
Vol 50 (7) ◽  
pp. 743-752
Author(s):  
Razvan Galalae ◽  
Jean-Michel Hannoun-Lévi
Keyword(s):  
Alternative Methods ◽  
Accelerated Partial Breast Irradiation ◽  
Partial Breast Irradiation ◽  
Radiation Toxicity ◽  
X Rays ◽  
Breast Irradiation ◽  
Patient Reported ◽  
Conventionally Fractionated ◽  
3D Crt

Abstract Accelerated partial breast irradiation (APBI) delivers a short course of adjuvant RT after breast conserving surgery to only a limited part of the breast where the tumor was located. This procedure requires expertise, good communication, and close collaboration between specialized surgeons and attending radiation oncologists with adequate intraoperative tumor bed clip marking. However, APBI offers several intrinsic benefits when compared with whole breast irradiation (WBIR) including reduced treatment time (1 versus 4–6 weeks) and better sparing of surrounding healthy tissues. The present publication reviews the APBI level 1-evidence provided with various radiation techniques supplemented by long-term experience obtained from large multi-institutional phase II studies. Additionally, it offers an outlook on recent research with ultra-short or single-fraction APBI courses and new brachytherapy sources. Mature data from three randomized controlled trials (RCTs) clearly prove the noninferiority of APBI with ‘only two techniques—1/MIBT (multicatheter interstitial brachytherapy) (two trials) and 2/intensity modulated radiotherapy (one trial)’—in terms of equivalent local control/overall survival to the previous standard ‘conventionally fractionated WBIR’. However, MIBT-APBI techniques were superior in both toxicity and patient-reported outcomes (PROs) versus WBIR at long-term follow-up. Currently, in RCT-setting, alternative APBI techniques such as intraoperative electrons, 50-kV x-rays and three-dimensional conformal external beam radiotherapy (3D-CRT) failed to demonstrate noninferiority to conventionally fractionated WBIR. However, 3D-CRT-APBI compared noninferior to hypo-fractionated WBIR in preventing ipsilateral breast tumor recurrence (randomized RAPID-trial) but was associated with a higher rate of late radiation toxicity. Ultimately, MIBT remains the only APBI modality with noninferior survival/superior toxicity/PROs at 10-years and therefore should be prioritized over alternative methods in patients with breast cancer considered at low-risk for local recurrence according to recent international guidelines.

Sign in / Sign up

Export Citation Format

Share Document